IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $53.58.

Several brokerages recently issued reports on IDYA. Stephens reissued an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Leerink Partners downgraded shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Finally, Wedbush reissued an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On IDEAYA Biosciences

Several large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter worth $47,000. Neo Ivy Capital Management acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter worth $3,361,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of IDEAYA Biosciences by 1.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,286 shares of the company's stock worth $8,308,000 after acquiring an additional 4,790 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of IDEAYA Biosciences by 50.7% in the fourth quarter. Voloridge Investment Management LLC now owns 286,759 shares of the company's stock worth $7,370,000 after acquiring an additional 96,466 shares in the last quarter. Finally, Woodline Partners LP increased its position in shares of IDEAYA Biosciences by 0.3% in the fourth quarter. Woodline Partners LP now owns 590,697 shares of the company's stock worth $15,181,000 after acquiring an additional 1,943 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

Remove Ads

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA traded down $0.34 on Friday, hitting $18.79. The company's stock had a trading volume of 1,197,399 shares, compared to its average volume of 895,573. IDEAYA Biosciences has a 12-month low of $18.20 and a 12-month high of $47.72. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -5.69 and a beta of 0.82. The stock has a 50 day moving average of $23.04 and a 200-day moving average of $28.32.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. Sell-side analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.